Revvity, Inc. (NYSE: RVTY) is a Healthcare company,
ranked #4,386 of 6,774 companies globally and #2,178 of 4,000 in United States on PositoAI,
with a Positivity Score of 19,526.
Its market capitalisation is ₹1.66 lakh Cr ($17.56B), P/E ratio is 75.3 and P/B ratio is 2.43.
It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
P/B Ratio2.43
P/E Ratio75.3
D/E Ratio0.46
ROE3.21%
Owes vs Owns ?0.40× Low$0.40 owed for every $1 it owns · balance sheet Jun 2026
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection…
What is Revvity, Inc.'s P/E and P/B ratio?
Revvity, Inc. has a P/E ratio of 75.3 and a P/B ratio of 2.43.
What is Revvity, Inc.'s debt-to-equity ratio?
Revvity, Inc. has a debt-to-equity ratio of 0.46.
How much does Revvity, Inc. owe compared with what it owns?
Revvity, Inc. owes $0.40 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Revvity, Inc.'s Positivity rank?
Revvity, Inc. is ranked #4,386 of 6,774 companies globally and #2,178 of 4,000 in United States on PositoAI, with a Positivity Score of 19,526.
Does Revvity, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Revvity, Inc..
Where can I read the latest news about Revvity, Inc.?
Recent headlines about Revvity, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Revvity, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Revvity, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.
0 / 1000
🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.
Disclaimer —
PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.